Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is -67.73% as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
AVLN Return on Invested Capital (ROIC) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON INVESTED CAPITAL (ROIC)
-67.73%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.39%
median of 664 covered companies
CURRENT VS SECTOR MEDIAN
-102.88%
vs the sector median at left
Avalyn Pharma Inc. Common Stock
Market Cap
$1.15B
Return on Invested Capital (ROIC)
-67.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.15B
Return on Invested Capital (ROIC)
3.72%
TTM Avg
3.50%
3Y Avg
1.32%
5Y Avg
-2.22%
Market Cap
$1.14B
Return on Invested Capital (ROIC)
-8.86%
TTM Avg
-9.81%
3Y Avg
-9.88%
5Y Avg
-6.15%
Market Cap
$1.17B
Return on Invested Capital (ROIC)
-12.53%
TTM Avg
-48.13%
3Y Avg
-43.32%
5Y Avg
-40.54%
Market Cap
$1.17B
Return on Invested Capital (ROIC)
-52.44%
TTM Avg
-96.82%
3Y Avg
-100.85%
5Y Avg
-77.97%
Market Cap
$1.13B
Return on Invested Capital (ROIC)
5.93%
TTM Avg
9.95%
3Y Avg
11.37%
5Y Avg
9.31%
Market Cap
$1.13B
Return on Invested Capital (ROIC)
1.81%
TTM Avg
7.83%
3Y Avg
4.30%
5Y Avg
3.30%
Market Cap
$1.11B
Return on Invested Capital (ROIC)
-42.98%
TTM Avg
-26.82%
3Y Avg
-23.95%
5Y Avg
-23.95%
Market Cap
$1.21B
Return on Invested Capital (ROIC)
9.48%
TTM Avg
1.29%
3Y Avg
-3.62%
5Y Avg
0.10%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.15B | -67.73% | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 3.72% | 3.50% | 1.32% | -2.22% |
| OPKO Health, Inc. (OPK)vs › | $1.14B | -8.86% | -9.81% | -9.88% | -6.15% |
| Nektar Therapeutics (NKTR)vs › | $1.17B | -12.53% | -48.13% | -43.32% | -40.54% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | -52.44% | -96.82% | -100.85% | -77.97% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 5.93% | 9.95% | 11.37% | 9.31% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 1.81% | 7.83% | 4.30% | 3.30% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.11B | -42.98% | -26.82% | -23.95% | -23.95% |
| Innovage Holding Corp. (INNV)vs › | $1.21B | 9.48% | 1.29% | -3.62% | 0.10% |
| MannKind Corporation (MNKD)vs › | $1.22B | 1.32% | 13.41% | 0.51% | -22.96% |
ROIC
-67.7%
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | -67.73% |
